<?xml version="1.0" encoding="UTF-8"?><marc:collection xmlns:marc="http://www.loc.gov/MARC21/slim">
  <marc:record>
    <marc:leader>00000nam  2200000za 4500</marc:leader>
    <marc:controlfield tag="001">9.820810</marc:controlfield>
    <marc:controlfield tag="003">CaOODSP</marc:controlfield>
    <marc:controlfield tag="005">20221107143316</marc:controlfield>
    <marc:controlfield tag="007">cr |||||||||||</marc:controlfield>
    <marc:controlfield tag="008">161102s2016    oncd    ob   f000 0 eng d</marc:controlfield>
    <marc:datafield tag="020" ind1=" " ind2=" ">
      <marc:subfield code="a">978-0-660-05838-2</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="040" ind1=" " ind2=" ">
      <marc:subfield code="a">CaOODSP</marc:subfield>
      <marc:subfield code="b">eng</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="043" ind1=" " ind2=" ">
      <marc:subfield code="a">n-cn---</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="086" ind1="1" ind2=" ">
      <marc:subfield code="a">HP40-160/2016E-PDF</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="245" ind1="0" ind2="0">
      <marc:subfield code="a">Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older </marc:subfield>
      <marc:subfield code="h">[electronic resource] : </marc:subfield>
      <marc:subfield code="b">interim recommendation.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="246" ind1="1" ind2=" ">
      <marc:subfield code="i">At head of title: </marc:subfield>
      <marc:subfield code="a">Advisory committee statement (ACS), National Advisory Committee on Immunization (NACI)</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="260" ind1=" " ind2=" ">
      <marc:subfield code="a">[Ottawa] : </marc:subfield>
      <marc:subfield code="b">Public Health Agency of Canada, </marc:subfield>
      <marc:subfield code="c">2016.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="300" ind1=" " ind2=" ">
      <marc:subfield code="a">27 p.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="500" ind1=" " ind2=" ">
      <marc:subfield code="a">Issued also in French under title: Mise à jour sur l’utilisation du vaccin conjugué 13-valent (Pneu-C-13) en plus du vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23) chez les adultes immunocompétents âgés de 65 ans et plus : recommandation provisoire.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="504" ind1=" " ind2=" ">
      <marc:subfield code="a">Includes bibliographical references.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="520" ind1=" " ind2=" ">
      <marc:subfield code="a">"The objective of this Statement Update is to provide evidence and interim recommendations for the use of PNEU-C-13 in immunocompetent adults over 65 years of age and to allow informed decision making in cases when PNEU-C-13 is being considered on an individual basis for use in this age group. This statement: updates the epidemiology of pneumococcal disease in Canada for strains prevented by PNEU-C-13 to the year of the most recently available data (2013); provides an update to the review of the literature on the use of PNEU-C-13 in immunocompetent adults, which includes the recently published CAPiTA trial, as well as randomised controlled trials (RCTs) that investigate safety and immunogenicity; and provides updated, interim, recommendations for the use of PNEU-C-13 in immunocompetent individuals who are 65 years of age and over“--Introduction, p. 5.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="692" ind1="0" ind2="7">
      <marc:subfield code="2">gccst</marc:subfield>
      <marc:subfield code="a">Influenza</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="692" ind1="0" ind2="7">
      <marc:subfield code="2">gccst</marc:subfield>
      <marc:subfield code="a">Immunization</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="692" ind1="0" ind2="7">
      <marc:subfield code="2">gccst</marc:subfield>
      <marc:subfield code="a">Seniors</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="710" ind1="1" ind2=" ">
      <marc:subfield code="a">Canada. </marc:subfield>
      <marc:subfield code="b">National Advisory Committee on Immunization.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="710" ind1="2" ind2=" ">
      <marc:subfield code="a">Public Health Agency of Canada.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="775" ind1="0" ind2="8">
      <marc:subfield code="t">Mise à jour sur l'utilisation du vaccin conjugué 13-valent (Pneu-C-13) en plus du vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23) chez les adultes immunocompétents âgés de 65 ans et plus </marc:subfield>
      <marc:subfield code="w">(CaOODSP)9.820811</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="856" ind1="4" ind2="0">
      <marc:subfield code="q">PDF</marc:subfield>
      <marc:subfield code="s">1.17 MB</marc:subfield>
      <marc:subfield code="u">https://publications.gc.ca/collections/collection_2016/aspc-phac/HP40-160-2016-eng.pdf</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="986" ind1=" " ind2=" ">
      <marc:subfield code="a">160085</marc:subfield>
    </marc:datafield>
  </marc:record>
</marc:collection>
